-
-
-
-
-
-
-
Xilio receives $35.8 million from warrant exercises, extends cash runway
-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Announces Pipeline and Business Updates, Reports Q4
-
-
-
-
-
-
-
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial
-
-
-
-
-
-
-
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
-
1,224,135 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

